NCT03955939View on ClinicalTrials.gov

A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 2, 2019

Primary Completion Date

May 14, 2020

Study Completion Date

May 14, 2020

Conditions

Metastatic Breast Cancer

Interventions

DRUG

LY3295668 Erbumine

Administered orally.

DRUG

Endocrine therapy

Administered according to label instructions.

DRUG

Midazolam

Administered orally.

Trial Locations (7)

1200

Cliniques Universitaires Saint-Luc, Brussels

2650

Universitair Ziekenhuis Antwerpen, Edegem

3000

Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven

9000

Universitair Ziekenhuis Gent, Ghent

91010-0269

City of Hope National Medical Center, Duarte

02115

Dana Farber Cancer Institute, Boston

78229-3307

South Texas Accelerated Research Therapeutics, LLC, San Antonio

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT03955939 - A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body | Biotech Hunter | Biotech Hunter